Novel Diagnosis and Therapeutic Strategies for Gestational Diabetes

A special issue of Diabetology (ISSN 2673-4540).

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 3035

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medicine and Aging and Center of Aging Science and Translational Medicine (CESI-Met), University of Chieti, 66100 Chieti, Italy
Interests: cancer; aging; diabetes; molecular; osteoporosis

Special Issue Information

Dear Colleagues,

As Guest Editor of this Special Issue of Diabetology titled "Novel Diagnosis and Therapeutic Strategies for Gestational Diabetes", I am inviting you to submit an original research article/review paper on the topic. Diabetology (ISSN 2673-4540) is an international open-access journal. 

In this Special Issue of Diabetology, we invite researchers to submit their works focusing on novel biomarkers and/or therapeutic targets in gestational diabetes.

The official deadline for submitting papers is 15 April 2022, and the instructions on how to proceed with writing will be available on a dedicated web page. Research areas may include (but are not limited to) the following:

  • Successful strategies to prevent GDM;
  • Biomarkers and mechanisms that can predict pregnancy complications, and on the long-term metabolic risk;
  • New therapeutic strategies on short- and long-term clinical outcomes of pregnancy complicated by gestational diabetes.

I look forward to receiving your contributions.

Dr. Rossella Liani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diabetology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gestational diabetes
  • transcriptomics
  • proteomics
  • biomarkers
  • therapeutic targets

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

8 pages, 232 KiB  
Article
Early Pregnancy Serum Concentration of Secreted Frizzled-Related Protein 4, Secreted Frizzled-Related Protein 5, and Chemerin in Obese Women Who Develop Gestational Diabetes Mellitus
by Rik H. J. Beernink, Joost H. N. Schuitemaker, Marijke M. Faas, Lucilla Poston and Sara L. White
Diabetology 2022, 3(1), 258-265; https://0-doi-org.brum.beds.ac.uk/10.3390/diabetology3010016 - 16 Mar 2022
Viewed by 2301
Abstract
Background: The aim of this study was to evaluate whether secreted frizzled-related protein 4 (sFRP4), secreted frizzled-related protein 5 (sFRP5), and chemerin serum concentrations in early pregnancy are associated with the development of gestational diabetes mellitus (GDM) in an obese cohort. In previous [...] Read more.
Background: The aim of this study was to evaluate whether secreted frizzled-related protein 4 (sFRP4), secreted frizzled-related protein 5 (sFRP5), and chemerin serum concentrations in early pregnancy are associated with the development of gestational diabetes mellitus (GDM) in an obese cohort. In previous studies, increased sFRP4 and chemerin, and decreased sFRP5 concentrations were associated with the development of GDM in normal and overweight women. Methods: In this exploratory case control study, sFRP4, sFRP5, and chemerin serum concentrations were determined by ELISA in 50 obese women who developed GDM and 100 uncomplicated control pregnancies. Serum samples were obtained between 15+0–18+6 weeks’ gestational age and based on a priori known associations with the development of GDM, body mass index (BMI) and maternal age were selected for adjustment in multivariate analyses. Results: In this obese cohort (median BMI 35.7 kg/m2, IQR 33.2–40.3 kg/m2), the biochemical markers showed no association with GDM: sFRP5 odds ratio (OR) 0.44 (95% confidence interval (CI) 0.01–23.18, p = 0.687), sFRP4 OR 0.55 (95% CI 0.09–3.52, p = 0.528), and chemerin OR 3.47 (95% CI 0.05–227.72, p = 0.560). Adjustment for BMI and maternal age did not influence the association. None of the markers were significantly correlated with insulin resistance (HOMA2-IR). Conclusion: No association was found between sFRP4, sFRP5, or chemerin concentration and the development of GDM in a cohort of obese pregnant women. The absence of the association may indicate that these proteins play a lesser biological role in the pathophysiology of GDM in obese women. Full article
(This article belongs to the Special Issue Novel Diagnosis and Therapeutic Strategies for Gestational Diabetes)
Back to TopTop